Clinical Trials Logo

Filter by:
NCT ID: NCT04620239 Recruiting - Clinical trials for Transitional Cell Cancer of Renal Pelvis and Ureter

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

UCM301
Start date: March 22, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase with the specific duration depending on the patient's response to treatment

NCT ID: NCT04616859 Recruiting - Healthy Clinical Trials

Binge Drinking of Alcohol Mixed With Energy Drinks

ENERGYBINGE
Start date: October 8, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)

NCT ID: NCT04616495 Recruiting - Colorectal Cancer Clinical Trials

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases

TRASMETIR
Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.

NCT ID: NCT04616326 Recruiting - Chronic Migraine Clinical Trials

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

REBUILD-2
Start date: November 25, 2020
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

NCT ID: NCT04615429 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.

NCT ID: NCT04615091 Recruiting - Clinical trials for Surgery--Complications

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Start date: August 30, 2020
Phase:
Study type: Observational

The ELASTO-SURGERY study aims to evaluate the prognostic role of portal hypertension evaluated by non-invasive methods in predicting post-operative morbidity (at 90 days) and mortality (at 365 days) in patients with advanced chronic liver disease undergoing elective extrahepatic surgery.

NCT ID: NCT04613921 Recruiting - Liver Cirrhosis Clinical Trials

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

CHANCE
Start date: July 8, 2021
Phase:
Study type: Observational

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.

NCT ID: NCT04613596 Recruiting - Clinical trials for Advanced Non-Small Cell Lung Cancer

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Start date: December 2, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are candidates for first line treatment.

NCT ID: NCT04612751 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

TROPION-Lung04
Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT04612569 Recruiting - Rectal Cancer Clinical Trials

Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.

PRELARS
Start date: October 1, 2020
Phase:
Study type: Observational

Patients with sphincter saving procedures of rectal cancer usually experience intestinal dysfunction, including difficulty emptying the bowel and faecal incontinence, leading to a detriment in the quality of life. A prospective study is proposed to measure de feasibility and the impact of a continuous care programme for the prevention or reduction of intestinal dysfunction disorders. The intervention lies on prehabilitation and rehabilitation with physiotherapy, biofeedback and neuromodulation, is assisted by a telematic information system (APP for the monitoring of education on physiotherapy and surveillance).